Thoracic SMARCA4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Newly identified thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UTs) show aggressive behavior and challenging diagnosis. Immunotherapy may improve outcomes for patients with these rare thoracic tumors.
Area Of Science
- Oncology
- Pathology
- Genetics
Background
- Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a new entity in the 2021 WHO classification.
- Diagnosis of SMARCA4-UTs can be difficult, particularly on small biopsy samples.
Purpose Of The Study
- To summarize the clinicopathological features of thoracic SMARCA4-UTs.
- To evaluate the prognostic significance and immunotherapy efficacy of thoracic SMARCA4-UTs.
Main Methods
- Retrospective analysis of 35 thoracic SMARCA4-UT cases from 2017-2022.
- Review of clinicopathological data, immunohistochemistry, and treatment outcomes.
- Assessment of immunotherapy response, including PD-L1 expression, TILs, and TMB.
Main Results
- All 35 patients were male smokers; common sites were the left upper lobe and mediastinum.
- Histology showed solid architecture (100%), rhabdoid morphology (51.4%), and necrosis (42.9%). CD34 and synaptophysin were frequently positive.
- Patients receiving immunotherapy showed improved overall survival (OS) and progression-free survival (PFS) compared to those who did not.
Conclusions
- Thoracic SMARCA4-UTs have an aggressive clinical course and characteristic histological features.
- Immunotherapy may be associated with positive responses in some patients with thoracic SMARCA4-UTs.
- Larger studies are needed to validate the efficacy of immunotherapy for these tumors.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
